Cipla profit up 73 per cent at Rs 412 crore in Q4
Drug major Cipla on Friday posted a 73 per cent rise in consolidated net profit at Rs 412 crore for the fourth quarter ended March 2021 on the back of robust sales across markets.
The Mumbai-based firm had reported a net profit of Rs 238 crore in January-March 2019-20. Total revenue from operations rose to Rs 4,606 crore from Rs 4,376 crore in the same period of 2019-20, Cipla said in a regulatory filing.
For the entire 2020-21 financial year, Cipla reported a consolidated net profit of Rs 2,389 crore against Rs 1,500 crore in 2019-20. Total revenue from operations in the last fiscal rose to Rs 19,160 crore against Rs 17,132 crore in 2019-20.
The company’s board has recommended a final dividend of Rs 5 per share (face value Rs 2 each) for 2020-21.
Dr Reddy’s Laboratories on Friday reported a 29 per cent decline in consolidated net profit at Rs 557 crore for the fourth quarter ended March 2021. The Hyderabad-based drug major had posted a net profit of Rs 781 crore in the January-March period of 2019-20. Net sales rose to Rs 4,608 crore in the quarter under review from Rs 4,336.1 crore in the fourth quarter of 2019-20.
Engineering and construction giant Larsen & Toubro (L&T) on Friday reported an 11.3 per cent rise in consolidated net profit at Rs 3,820.16 crore for the March quarter of 2020-21 on the back of higher revenue from operations. The company had posted a net profit of Rs 3,430.10 crore in the year-ago period, L&T said in a filing to BSE.
The income of the company during the January-March period increased to Rs 49,116.16 crore from Rs 44,905.76 crore in the year-ago period, the filing said.